• Publications
  • Influence
Acute myeloid leukemia.
TLDR
Recent advances in understanding of the pathophysiology of acute myeloid leukemia (AML) and allied conditions are reviewed, including the advanced myelodysplastic syndromes (MDS), while Drs.
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
TLDR
Nilotinib has a relatively favorable safety profile and is active in imatinib-resistant CML, and common adverse events were myelosuppression, transient indirect hyperbilirubinemia, and rashes.
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
TLDR
FCR produced a high CR rate in previously untreated CLL, and most patients had no detectable disease on flow cytometry at the end of therapy.
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
TLDR
Hyper-CVAD therapy is superior to previous regimens and should be compared with established regimens in adult ALL, and a smaller percentage had more than 5% day 14 blasts and better survival.
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
TLDR
Results show that FLT3 inhibition is associated with clinical activity in AML patients harboringFLT3-activating mutations and indicate that CEP-701 holds promise as a novel, molecularly targeted therapy for this disease.
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.
TLDR
Patients who underwent allogeneic SCT as postremission therapy had longer survival than patients who achieved remission and received no additional therapy or patients who underwentAllogeneic or autologous SCTAs salvage therapy as salvage therapy.
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase
TLDR
Nilotinib is highly active and safe in patients with CML-CP after imatinib failure or intolerance and was effective in patients harboring BCR-ABL mutations associated with imatinIB resistance (except T315I), and also in Patients with a resistance mechanism independent of B CR-ABl mutations.
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
TLDR
It is concluded that a low-dose, dose-intensity schedule of decitabine optimizes epigenetic modulation and clinical responses in MDS.
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
TLDR
It is concluded that decitabine is effective in myeloid malignancies, and low doses are as or more effective than higher doses.
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
TLDR
The multiple functions of Survivin in the regulation of apoptosis, the promotion of tumorigenesis, and the development of survivin inhibitors as a novel anticancer therapeutic strategy are reviewed.
...
...